IS5378A - Apríl-nýstárlegt prótín sem hefur áhrif á vöxt - Google Patents

Apríl-nýstárlegt prótín sem hefur áhrif á vöxt

Info

Publication number
IS5378A
IS5378A IS5378A IS5378A IS5378A IS 5378 A IS5378 A IS 5378A IS 5378 A IS5378 A IS 5378A IS 5378 A IS5378 A IS 5378A IS 5378 A IS5378 A IS 5378A
Authority
IS
Iceland
Prior art keywords
april
affects growth
innovative protein
innovative
protein
Prior art date
Application number
IS5378A
Other languages
English (en)
Inventor
Tschopp Jurg
Original Assignee
Apotech Research And Development Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotech Research And Development Ltd. filed Critical Apotech Research And Development Ltd.
Publication of IS5378A publication Critical patent/IS5378A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS5378A 1997-09-12 2000-02-18 Apríl-nýstárlegt prótín sem hefur áhrif á vöxt IS5378A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
US7938498P 1998-03-26 1998-03-26
PCT/US1998/019191 WO1999012965A2 (en) 1997-09-12 1998-09-11 April- a novel protein with growth effects

Publications (1)

Publication Number Publication Date
IS5378A true IS5378A (is) 2000-02-18

Family

ID=26738027

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5378A IS5378A (is) 1997-09-12 2000-02-18 Apríl-nýstárlegt prótín sem hefur áhrif á vöxt

Country Status (20)

Country Link
US (3) US20030138884A1 (is)
EP (1) EP1027431A2 (is)
JP (1) JP2001515712A (is)
KR (1) KR100618492B1 (is)
CN (1) CN1195849C (is)
AU (1) AU759717B2 (is)
BR (1) BR9812634A (is)
CA (1) CA2303615A1 (is)
CZ (1) CZ294615B6 (is)
EA (1) EA005411B1 (is)
EE (1) EE200000147A (is)
HU (1) HUP0004611A3 (is)
IL (1) IL134537A0 (is)
IS (1) IS5378A (is)
NO (1) NO20001242L (is)
NZ (1) NZ503850A (is)
PL (1) PL339463A1 (is)
SK (1) SK3542000A3 (is)
TR (1) TR200000669T2 (is)
WO (1) WO1999012965A2 (is)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
AU5201399A (en) * 1997-09-30 1999-10-18 Pharmacia & Upjohn Company Tnf-related death ligand
WO1999026976A1 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
WO2000043032A2 (en) 1999-01-25 2000-07-27 Biogen, Inc. Baff, inhibitors thereof and their use in the modulation of b-cell response
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
BR0013391A (pt) * 1999-08-17 2002-07-09 Biogen Inc Uso do receptor baff (bcma) como um agente imunoregulador
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001025256A2 (en) * 1999-10-06 2001-04-12 University Of Utah Research Foundation Trdl-1-gamma, a novel tumor necrosis-like ligand
CA2399387C (en) 2000-02-11 2015-11-03 Biogen, Inc. Heterologous polypeptide of the tnf family
AU2006201471B2 (en) * 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
IL150755A0 (en) * 2000-02-16 2003-02-12 Genentech Inc Uses of agonists and antagonists to modulate activity of tnf-related molecules
CA2408617A1 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP2431054A3 (en) * 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
GB2370273A (en) * 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
DK1436003T3 (da) 2001-05-24 2010-03-15 Zymogenetics Inc TACI-immunoglobulin-fusionsproteiner
WO2002094192A2 (en) 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
US20030166559A1 (en) 2002-01-04 2003-09-04 Desjarlais John R. Dominant negative proteins and methods thereof
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
WO2004089982A2 (en) * 2003-01-06 2004-10-21 Xencor April variants and methods thereof
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
JP2008505607A (ja) * 2004-01-29 2008-02-28 ジェネンテック・インコーポレーテッド Ｂｃｍａの細胞外ドメインの変異体とその使用法
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
JP2008525002A (ja) 2004-12-23 2008-07-17 ラボラトワール セローノ ソシエテ アノニム Ｂｃｍａポリペプチド及びその使用
CA2618763A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
CN101262876A (zh) 2005-08-09 2008-09-10 酶遗传学股份有限公司 用taci-ig融合分子治疗b细胞恶性肿瘤的方法
WO2007039489A1 (en) * 2005-09-26 2007-04-12 Apotech Corporation Antibodies against april as biomarkers for early prognosis of lymphoma patients
EP3037544A1 (en) 2005-10-13 2016-06-29 Human Genome Sciences, Inc. Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
KR20090016707A (ko) 2006-05-15 2009-02-17 아레스 트레이딩 에스.에이. Ｔａｃｉ­ｉｇ 융합 분자를 사용하여 자가면역 질병을 치료하는 방법
HUE027826T2 (en) 2009-03-02 2016-11-28 Aduro Biotech Holdings Europe B V Anti-proliferative Ligand Antibodies (APRIL)
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
WO2011108937A1 (en) * 2010-03-05 2011-09-09 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam B-cell stimulating fusion proteins of an antigen with baff or april
NL2011406C2 (en) * 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
DK3434101T5 (da) * 2013-09-23 2024-09-16 Regeneron Pharma Ikke-menneskelige dyr, der har et humaniseret signalregulerende proteingen
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
SG10201811701YA (en) * 2013-11-19 2019-01-30 Regeneron Pharma Non-human animals having a humanized a proliferation-inducing ligand gene
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
CA3006058A1 (en) 2015-11-25 2017-06-01 Visterra, Inc. Antibody molecules to april and uses thereof
KR20230135562A (ko) 2020-10-29 2023-09-25 인더스트리얼 폴리머스 앤드 케미컬스, 인크. 병원체 모니터링 및 불활성화를 갖는 공기 필터
AU2022327178A1 (en) 2021-08-11 2024-03-28 Akso Biopharmaceutical, Inc. METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF
AU2024239150A1 (en) 2023-03-21 2025-10-02 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
CN118909083A (zh) * 2024-07-30 2024-11-08 江苏省农业科学院 一种猪b细胞增殖诱导配体蛋白及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
AU6166396A (en) * 1995-06-07 1996-12-30 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical prepara tions
US6509170B1 (en) * 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
JP2001501453A (ja) * 1996-03-14 2001-02-06 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ヒト腫瘍壊死因子δおよびε
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease

Also Published As

Publication number Publication date
EA005411B1 (ru) 2005-02-24
EE200000147A (et) 2001-02-15
JP2001515712A (ja) 2001-09-25
US20060084148A1 (en) 2006-04-20
WO1999012965A2 (en) 1999-03-18
BR9812634A (pt) 2000-08-22
PL339463A1 (en) 2000-12-18
CZ294615B6 (cs) 2005-02-16
HUP0004611A2 (hu) 2001-04-28
NO20001242L (no) 2000-05-11
TR200000669T2 (tr) 2000-08-21
EP1027431A2 (en) 2000-08-16
AU9316298A (en) 1999-03-29
CA2303615A1 (en) 1999-03-18
US20050112596A1 (en) 2005-05-26
KR100618492B1 (ko) 2006-08-31
CN1270632A (zh) 2000-10-18
CZ2000869A3 (cs) 2000-09-13
CN1195849C (zh) 2005-04-06
SK3542000A3 (en) 2000-08-14
HUP0004611A3 (en) 2002-04-29
EA200000310A1 (ru) 2000-10-30
IL134537A0 (en) 2001-04-30
NO20001242D0 (no) 2000-03-09
US20030138884A1 (en) 2003-07-24
NZ503850A (en) 2002-12-20
WO1999012965A3 (en) 1999-06-03
KR20010023893A (ko) 2001-03-26
AU759717B2 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
IS5378A (is) Apríl-nýstárlegt prótín sem hefur áhrif á vöxt
DE69729021D1 (de) Flächiges Implantat
DE69800491D1 (de) Baumschere
NO2010022I1 (no) Denosumab
NO982097D0 (no) Peptider
DE69725567D1 (de) Haltetransplantat
NO982098D0 (no) Peptider
ITMI992109A0 (it) Innesto
DE69925271D1 (de) Angiostatin-bindendes protein
TR199701666A3 (tr) Sismanliga karsi proteinler
GB9828704D0 (en) Proteins
GB9816337D0 (en) Proteins
GB9828880D0 (en) Protein
DE59810662D1 (de) Koaxialverbinder
ID20403A (id) PEMBUATAN α-TOKOFEROL
ATE266679T1 (de) Wachse
GB9819038D0 (en) Protein
GB9812607D0 (en) Protein
GB9809566D0 (en) Protein
KR970020372U (ko) 장제용 화환
GB9816335D0 (en) Proteins
GB9816336D0 (en) Proteins
GB0315759D0 (en) Proteins
DK1088069T3 (da) Angiostatin-bindende protein
GB9823975D0 (en) Protein